SPRO (Spero Therapeutics) Shiller PE Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPRO Spero Therapeutics Inc SPRO
66 GF Score
Price $1.21
GF Value $1.05
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Spero Therapeutics  (NAS:SPRO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Spero Therapeutics Shiller PE Ratio Related Terms


Spero Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Shiller PE Ratio Chart

Spero Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spero Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SPRO vs ACRV, BSEM, RNTX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Spero Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Shiller PE Ratio falls into.


SPRO
66GF Score
Spero Therapeutics Inc SPRO
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Spero Therapeutics's E10 for the quarter that ended in Mar. 2026 is calculated as:

For example, Spero Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.13/330.2130*330.2130
=-0.130

Current CPI (Mar. 2026) = 330.2130.

Spero Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201512 0.000 236.525 0.000
201609 -1.122 241.428 -1.535
201612 -1.262 241.432 -1.726
201703 -1.080 243.801 -1.463
201706 -1.835 244.955 -2.474
201709 -0.901 246.819 -1.205
201712 -1.590 246.524 -2.130
201803 -0.740 249.554 -0.979
201806 -0.690 251.989 -0.904
201809 -0.600 252.439 -0.785
201812 -0.600 251.233 -0.789
201903 -0.290 254.202 -0.377
201906 -0.740 256.143 -0.954
201909 -0.950 256.759 -1.222
201912 -1.320 256.974 -1.696
202003 -1.220 258.115 -1.561
202006 -0.850 257.797 -1.089
202009 -0.860 260.280 -1.091
202012 -0.680 260.474 -0.862
202103 -0.660 264.877 -0.823
202106 -0.630 271.696 -0.766
202109 -0.700 274.310 -0.843
202112 -0.920 278.802 -1.090
202203 -1.010 287.504 -1.160
202206 -0.870 296.311 -0.970
202209 -0.330 296.808 -0.367
202212 0.550 296.797 0.612
202303 -0.250 301.836 -0.274
202306 -0.230 305.109 -0.249
202309 -0.060 307.789 -0.064
202312 0.970 306.746 1.044
202403 -0.240 312.332 -0.254
202406 -0.330 314.175 -0.347
202409 -0.320 315.301 -0.335
202412 -0.380 315.605 -0.398
202503 -0.250 319.799 -0.258
202506 -0.030 322.561 -0.031
202509 -0.130 324.800 -0.132
202512 0.530 324.054 0.540
202603 -0.130 330.213 -0.130

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $1.21 is trading 15.2% above its estimated GF Value™ of $1.05. GuruFocus considers Spero Therapeutics to be Modestly Overvalued.

Key valuation signals for SPRO:

  • Shiller PE Ratio:
  • GF Value™: $1.05 vs. price of $1.21 (15.2% above fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spero Therapeutics Business Description

Other Exchanges 2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
66GF Score

Get the complete analysis for SPRO

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.21
Price
$1.05
GF Value